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I. Introduction
“Receptors recognize a distinct chemical entity and translate information from that entity 
into a form that the cell can read to alter its state” (Kenakin et al., 1992). Even though the 
receptors are often pharmacologically defined on the basis of synthetic compounds, they are 
assumed to have developed to respond to endogenous molecules. Therefore, receptors are 
generally named on the basis of their natural ligands. Hence, it is appropriate to very briefly 
summarize the evidence that purine nucleotides and nucleosides are natural ligands for a 
wide class of receptors.
In a seminal paper, Drury and Szent-Györgyi (1929) showed that adenosine exerted a large 
number of biological effects, including bradycardia and vasodilation. A wider interest in the 
role of adenosine followed from the demonstration in 1963 that adenosine can be produced 
by the hypoxic heart. Two groups independently formulated the hypothesis that adenosine 
may be involved in the metabolic regulation of coronary blood flow (Berne, 1963; Gerlach et 
al., 1963). The observation by de Gubareff and Sleator (1965) that the actions of adenosine 
in heart tissue could be blocked by caffeine suggested the existence of an adenosine receptor. 
The potent cardiovascular effects of adenosine led to an interest in the synthesis of new 
adenosine analogs, and careful dose-response studies with a number of these drugs (Cobbin 
et al., 1974) strongly suggested the presence of a receptor for adenosine-like compounds. 
Sattin and Rall (1970) reported that adenosine increased cyclic AMP accumulation in slices 
of rodent brain and that this adenosine-induced second-messenger response was blocked by 
methylxanthines. Their findings suggested that adenosine receptors exist in the central 
nervous system. The essentially simultaneous findings by Mcilwain (1972), that such brain 
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slices actually elaborate adenosine in concentrations that would be sufficient to elevate 
cyclic AMP, provided support that these putative receptors were physiologically occupied by 
adenosine. Thus, in the 1970s there was good evidence that there were receptors for 
adenosine at which methylxanthines acted as antagonists. Biochemical evidence for the 
existence of multiple adenosine receptors was subsequently provided by the demonstration 
that adenosine analogs increased cyclic AMP production in some preparations and decreased 
it in others. Because the relative agonist potency for a variety of adenosine analogs was 
different for these two types of effects, the presence of two classes of receptors, called A1 
and A2 (van Calker et al., 1979) or Ri and Ra (Londos et al., 1980), was proposed. The 
A1/A2 nomenclature is now generally used.
The presence of receptors for ADP, particularly on blood platelets, was also recognized 
several decades ago. Studies of the factors in blood that induce platelet aggregation led to 
the identification of ADP as an active component present in red blood cell extracts (Gaarder 
et al., 1961). The evidence that ADP and adenosine (presumably A2) receptors exist on 
platelets was summarized by Haslam and Cusack (1981).
Four decades ago, ATP was shown to produce important cardiovascular effects (Green and 
Stoner, 1950) and to be released from sensory nerves (Holton and Holton, 1954; Holton, 
1959), hinting at a role in neural transmission. In his landmark review of purinergic nerves, 
Burnstock (1972) postulated the existence of specific ATP receptors. Although evidence in 
support of this idea was not overwhelming at the time, many subsequent studies have 
supported the existence of receptors for extracellular ATP (Burnstock and Brown, 1981; 
Gordon, 1986; O’Connor et al., 1991). Similarly, the evidence is now compelling that ATP 
plays important physiological and/ or pathophysiological roles in a variety of biological 
systems, including that of a neurotransmitter in peripheral and central neurons. Finally, 
diadenosinetetraphosphate is a dinucleotide stored in synaptic vesicles and chromaffin 
granules (Flodgaard and Klenow, 1982; Rodriguez del Castillo et al., 1988) and released 
therefrom (Pintor et al., 1991a, 1992). The purine dinucleotide also binds with 
subnanomolar affinity to receptors (Pintor et al., 1991b, 1993) and exerts biological effects 
(Pintor et al., 1993), indicating that it is an endogenous purinoceptor ligand.
Thus, strong evidence for the presence of receptors for the endogenous ligands adenosine, 
ADP, ATP, and dia-denosinetetraphosphate had accumulated. This group of receptors is 
called the purinoceptors. If at some future time there is compelling evidence that UTP, or 
another pyrimidine nucleotide, is an endogenous ligand at receptors that respond poorly or 
not at all to ATP, then this terminology may need revision.
II. General Considerations concerning the Classification of Purinoceptors
Classification of receptors should preferably be based on combined structural and 
pharmacological information (Kenakin et al., 1992). We are not yet in this ideal situation in 
the area of purinoceptors, and any proposed classification scheme by necessity must be 
tentative. In 1978 Burnstock made the important suggestion that there exists a family of 
receptors called purinergic receptors that can be subgrouped into two subclasses, P1 and P2 
(Burnstock, 1978). A somewhat extended version of this classification scheme (Burnstock, 
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1980) is shown in table 1. The scheme has been extremely influential and was adopted by 
numerous authors in the field. It should, however, be borne in mind that the original criteria 
have been continuously updated and modified with the availability of new information (see 
footnotes to table 1). The current criteria for the subclassification are summarized table 2.
Structural information is now available for several subtypes of receptors for adenosine 
(Maenhaut et al., 1990; Libert et al., 1991; Mahan et al., 1991; Fink et al., 1992; Stehle et 
al., 1992; Salvatore et al., 1992; Zhou et al., 1992). The same is true for some P2 receptors 
(Lustig et al., 1993; Webb et al., 1993; for comparisons between several recombinant P2 
receptors, see Barnard et al., 1994). Often, but not always, the information from the cloned 
receptors has supported earlier attempts at classification based on pharmacological criteria. 
Only limited structural information is presently available for receptors for adenine 
nucleotides. Thus, the current recommendations about the classification of receptors for 
adenosine are firmer than those regarding the adenine nucleotides. The pharmacological 
evidence is also more substantial in the case of the adenosine receptors than in the case of 
receptors for adenine nucleotides.
It has been strongly emphasized that antagonists, rather than agonists, are the preferred tools 
for pharmacological classification (Kenakin et al., 1992). The reason for this is that apparent 
agonist potency depends strongly not only on agonist binding to the receptor but also on the 
entire signal transduction machinery. Unfortunately, much of the pharmacological 
classification in the purinoceptor field rests on relative agonist potencies. Antagonists at 
adenosine receptors in many instances do not show the degree of selectivity that is ideal. 
Binding assays can be used for some of the receptors, but ligands are lacking for others. 
Thus, comparisons between receptors often have been based on different types of assays. In 
the case of receptors for ADP and ATP, classification is even more problematic in that 
currently available antagonists have not been unequivocally shown to be specific and 
selective.
One final consideration is of particular importance in the area of purinoceptors. It has been 
emphasized that extreme care must be taken to ensure that assays of biological activity are 
carried out under equilibrium conditions and that complications due to sites of loss or the 
influence of endogenous ligands are avoided (Kenakin et al., 1992). Because the purine 
nucleosides and nucleotides are extremely important metabolically, cells have elaborated 
very efficient systems for their degradation and/or uptake into cells. Such removal 
mechanisms are present on virtually all cells; this is in contrast to the situation for many 
neurotransmitters, for which sites of loss are particularly abundant in the nerves that use 
them but virtually absent elsewhere. Adenosine and several adenosine analogs are rapidly 
taken up and/or metabolized by transporters and enzymes. The efficiency of this process is 
extraordinary; the half-life of adenosine injected into the blood stream is on the order of 1 
second (Möser et al., 1989). Nucleotides are also very rapidly degraded, and the degradation 
products are taken up by cells. Some of the nucleotide analogs and their breakdown products 
interfere not only with the receptors but also with the removal systems. Conversely, the 
available agents that may reduce the breakdown of the nucleotides have the possibility of 
interacting with the receptors. Finally, it is often difficult to achieve a temporal equilibrium 
in the case of at least some adenine nucleotide receptors, which desensitize very rapidly. 
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Consequently, the evidence for subtypes of adenine nucleotide receptors that is based on 
relative agonist potency in complex biological systems must be regarded as tentative rather 
than definitive.
The IUPHAR receptor nomenclature committee also has suggested that classification-
neutral labels such as 1–2–3 are to be preferred to other labels. In the case of purinoceptors, 
Burnstock (1978, 1980) proposed a P1 and P2 nomenclature for adenosine and adenine 
nucleotide (ATP, ADP) receptors, respectively. A classification into A1 and A2 adenosine 
receptors was proposed in 1979 (van Calker et al., 1979) and is now generally accepted, 
along with the A2a and A2b nomenclature. The basis for the latter is that the two cloned 
receptors show considerable sequence homology and essentially similar signal transduction 
mechanisms and can be readily distinguished based on pharmacological criteria. The P1 
receptor designation is particularly used to contrast it with P2 receptors. A series of letters 
has been allocated in a rather random manner (P2X, P2Y, P2T, P2S, P2N, P2U, P2Z, P2D) for 
the adenine nucleotide receptors.
III. Proposed Receptor Classification
A. Adenosine (P1) Receptors
The terms adenosine receptor or P1 purinoceptor are used to designate this family of 
receptors. The term P1 is useful in situations in which comparison is made between P1 and 
P2 purinoceptors. The subtypes of adenosine/P1 purinoceptors are designated as A1, A2, A3,
… receptors and can be further divided, e.g., into A2a, A2b (table 3); this is in agreement 
with the above-mentioned general recommendation for subtype numbering of the IUPHAR 
committee on receptor nomenclature. Additions of receptors into this scheme will be made 
if, and only if, both structural and pharmacological evidence indicate a specific subtype. 
Such criteria involve evidence that the structure is different from that of already established 
members of the adenosine family in the same species. This information must be 
supplemented by the demonstration that either the receptor has a unique distribution among 
cells and tissues or the cloned receptor exhibits a unique pharmacology. Because all 
adenosine receptors as yet characterized are G-protein coupled (see below), unique 
pharmacology should be demonstrated in an expression system in which the receptor 
couples to relevant G-proteins.
The predicted amino acid sequences of some of the recombinant adenosine receptors are 
shown in figure 1. There appear to be four major classes of these receptors. The A2a 
receptors are similar to the A2b receptors in the transmembrane parts but differ from the A2b 
(and other adenosine receptor types) in having a considerably larger COOH-terminal 
domain. There are differences in the primary structure of adenosine receptors of a single 
subtype cloned from different species, which may help to explain the differences that have 
been shown in binding studies (Ferkany et al., 1986; Stone et al., 1988).
G-protein-coupled receptors show some structural similarities with bacteriorhodopsin, the 
structure of which has been determined with high-resolution electron cryomicroscopy 
(Henderson et al., 1990). Three-dimensional models of G-protein-coupled receptors may be 
constructed using this as a template (Hibert et al., 1991; Dudley et al., 1993), and attempts to 
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model the ligand-receptor interaction have been made (van Galen et al., 1990; van der 
Wenden et al., 1992). Functional models of the adenosine receptors may serve as an aid in 
the synthesis of novel ligands (Ijzerman et al., 1992; van Galen et al., 1992; Jacobson et al., 
1993b). A schematic representation of some aspects of these models is shown as figure 2.
All of the recombinant adenosine receptors have the general structure that would place them 
in the rhodopsin-like group of the superfamily of G-protein-coupled receptors. The A2 
receptors have been defined on the basis of their ability to stimulate adenylyl cyclase. Thus, 
they probably interact with the G-protein, Gs. It is not known whether there are other G-
proteins that can interact with A2 receptors. Similarly, it is not known whether Gs activated 
by adenosine receptors can interact with effectors other than adenylyl cyclase (cf. the β-
adrenoceptor in the heart which activates a Ca2+ channel via Gs), but experience from other 
signal transduction cascades suggests that this is a distinct possibility.
The A1 receptor has been shown to couple with Gi-1, Gi-2, Gi-3, and Go but not with Gs or Gz 
(Freissmuth et al., 1991; Munshi et al., 1991). In practically all instances (but see Fredholm 
et al., 1989; Thompson et al., 1992), responses to adenosine A1 receptor activation are 
blocked by pertussis toxin, which is compatible with an involvement of the Gi/Go family of 
G-proteins. In agreement with this, adenosine A1 receptors can induce a variety of different 
cellular responses, including inhibition of adenylyl cyclase (van Calker et al., 1978; Londos 
et al., 1980), stimulation of K+ conductance (Trussell and Jackson, 1985), inhibition of a 
Ca2+ conductance, probably through an N-type channel (Scholz and Miller, 1991), 
stimulation of phospholipase C, and generation of a Ca2+ and protein kinase C signal 
(Gerwins and Fredholm, 1992, 1994). Other reported effects include inhibition of inositol 
phospholipid hydrolysis (Kendall and Hill, 1988; Delahunty and Linden, 1988) and 
inhibition of transmitter release by a mechanism that does not involve a change in membrane 
K+ and Ca2+ conductances (Scholz and Miller, 1991). Based on evidence from other G-
protein-coupled receptors it seems likely that some of these responses are mediated by the α-
subunits of the G-proteins, whereas other effects may be due to the β,γ-subunits 
(Birnbaumer, 1992). Probably the degree of activation of the G-protein, and hence of the 
receptor, may differ by orders of magnitude depending on which subunit(s) mediates the 
response (Birnbaumer, 1992). The broad range of signaling responses emphasizes that it is 
not fruitful to attempt to subclassify adenosine receptors solely on the basis of whether the 
effects are mediated via cyclic AMP or not (Ribeiro and Sebastiao, 1986; Fredholm and 
Dunwiddie, 1988). Furthermore, the absolute potency of agonists in producing an effect 
cannot be used to classify receptors. Regarding the newly identified A3 receptor (Zhou et al., 
1992; Meyerhof et al., 1991), little is so far known about its G-protein coupling. Because A3 
receptors mediate inhibition of adenylyl cyclase, a Gi-like protein is a probable partner.
A list of drugs that appear to be useful to classify adenosine receptors is given in figure 3. 
The battery of pharmacological tools currently available for the classification of adenosine 
receptors is far from optimal, especially for use in a functional context, and some points 
need to be emphasized.
First, sensitivity to methylxanthines cannot be taken as a universal sign of adenosine 
receptor involvement. Methylxanthine-induced blockade of a response is still highly 
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suggestive of an involvement of adenosine receptors, but a lack of inhibition can no longer 
be taken as conclusive evidence against an adenosine receptor being involved. Because the 
methylxanthine-insensitive A3 receptor (table 3) may be present in significant quantities 
outside the testis, several older reports of methylxanthine-insensitive adenosine effects may 
have to be reinterpreted. Indeed, in a recent report it was shown that N6-2-(4-
aminophenyl)ethyladenosine which shows a high affinity for the A3 receptors (Zhou et al., 
1992) produces xanthine-insensitive hypotension in pithed rats (Fozard and Carruthers, 
1993). The A3 receptor also appears to mediate xanthine-resistant adenosine actions on mast 
cells (Ramkumar et al., 1993). It was recently found that N6-benzyl-5′-N-ethyl-
carboxamidoadenosine may be an A3-selective agonist (14-fold vs. A1 and A2a receptors; 
van Galen et al., 1993). Some 8-phenyl-substituted xanthines are potent antagonists, BW-A 
522 being the most potent, with nanomolar affinities at least at ovine and human A3 
receptors (Linden et al., 1993a; Salvatore et al., 1993; Fozard and Hannon, 1993).
Second, antagonists that are both selective and easily soluble are established for the A1 
receptor type. However, both absolute and relative potencies for these selective antagonists 
at A1 receptors may differ among species. The more selective antagonists at A2 receptors 
(Sarges et al., 1990; Shimada et al., 1992) have usually not been examined in well-
characterized functional systems, and information derives mainly from binding assays. 
Recent data indicate that l,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine is a 
selective A2a antagonist in functional assays (Shimada et al., 1992; Fredholm et al., 
unpublished observations). A related xanthine, 8-(3-chlorostyryl)caffeine, was recently 
found to be a very selective A2a antagonist (vs. A1), also in vivo (Jacobson et al., 1993b). A 
whole family of 8-styrylxanthines with A2a selectivity and varying physicochemical 
properties has been described (Jacobson et al., 1993a). These compounds are not yet readily 
available, which limits their usefulness in defining criteria for receptor classification.
Third, CGS 21680 and other 2-substituted adenosine analogs play an important role in 
pharmacological sub-classification of A2 receptors. These compounds discriminate well 
between A2a and A2b receptors. Cellular responses to CGS 21680 (and related compounds) 
may in addition depend critically on factors, such as receptor density and amounts and types 
of G-proteins and adenylyl cyclases, and not solely on the presence or absence of a specific 
adenosine A2a receptor subtype. However, recent data suggest that CGS 21680 may also 
bind to a structure, which may be a functional receptor, that is different from hitherto 
recognized adenosine receptors (Johansson et al., 1993; Cunha, Johansson, and Fred-holm, 
unpublished data).
B. P2/ATP Purinoceptors
The first overview of the functional effects of various ATP analogs was given by Burnstock 
and Kennedy (1985). By analyzing the nature of the responses to ATP and related 
compounds in a number of different biological systems, they discriminated between two 
major classes of receptors that were named P2X and P2Y purinoceptors, respectively. The 
two postulated P2 receptors were discriminated on the basis of response profiles to a number 
of ATP analogs: αβ-MeATP > βγ-MeATP > ATP = 2-MeSATP = ADP for the P2X subtype; 
2-MeSATP > ATP >> αβ-MeATP = βγ-MeATP for the P2Y subtype. P2X receptors were also 
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proposed to be quickly desensitized by αβ-MeATP. The agonist response profiles in the 
guinea pig isolated bladder and taenia coli were considered to represent prototypical P2X and 
P2Y receptors (Burnstock, 1991; Cusack, 1993). These studies were extended to other 
smooth muscle preparations, and P2X and P2Y purinoceptor activation was correlated with 
contraction and relaxation, respectively, but exceptions have been noted (Bailey and 
Hourani, 1992). The classification (table 4) rests very much on the potency of 
phosphothioate ATP derivatives, which were originally thought to be “nonhydrolyzable,” but 
many have more recently been shown to be degraded by ectonucleotidases (Cusack, 1993). 
Among the analogs 2-MeSATP, αβ-MeATP, L-βγ-MeATP may be particularly useful in 
discriminating between P2X and P2Y receptors (Hourani et al., 1985). Desensitization by αβ-
MeATP and ANAPP3 (table 4) has so far not been reported to occur except at P2X receptors. 
Novel selective agonists for P2X and P2Y receptors have been introduced (Fischer et al., 
1993; Burnstock et al., 1994), and studies with these ligands suggest that the receptors may 
exist in several subtypes.
Most recent evidence suggests that the P2X purinoceptor family represents an intrinsic ion 
channel permeable to Na+, K+, and Ca2+ (Bean, 1992). P2Y purinoceptors constitute G-
protein-linked receptors, often coupled to stimulation of phospholipase C activity and, 
hence, to inositol trisphosphate formation (O’Connor et al., 1991), but additional 
transduction mechanisms, including modulation of cyclic AMP generation (Okajima et al., 
1989; Yamada et al., 1992; Boyer et al., 1993) and arachidonic acid mobilization (Bruner 
and Murphy, 1990, 1993) have also been demonstrated.
After the 1985 Burnstock and Kennedy proposal, Gordon (1986) further subdivided the P2 
purinoceptors by assigning the name P2T to the receptor for ADP on blood platelets 
(Humphries et al., 1993) and P2Z for the “receptor” that mediates responses to ATP4− in 
mast cells (Dahlqvist and Diamant, 1974) and macrophages (Steinberg and Silverstein, 
1987), which appears to represent the opening of a fairly nonselective type of pore. There is 
now good evidence that there are receptors that respond to UTP, ATP, and ATPγS, but not to 
2-MeSATP or αβ-MeATP, which has led to the definition of the so-called “P2U” or 
“nucleotide” or “pyrimidine” receptor (table 4; O’Connor et al., 1991; Dubyak, 1991). There 
also appears to be a receptor for diadenosinetetraphosphate, which was called a P2D subtype 
(Hilderman et al., 1991; Castro et al., 1992). Some characteristics of the P2 purinoceptors are 
summarized in table 4.
A problem that has always hampered research in the P2 purinoceptor field is the lack of 
selective antagonists. The trypanoside suramin (Dunn and Blakeley, 1988; Voogd et al., 
1993) sometimes behaves as a competitive antagonist but does not appear to distinguish 
between the P2X and P2Y subtypes (Hoyle et al., 1990). Suramin is also very effective in 
inhibiting the actions of certain growth factors (Betsholtz et al., 1986; Peng et al., 1991), 
presumably secondarily to interactions with the corresponding receptors (Eriksson et al., 
1991). The potency of suramin against basic fibroblast growth factor (Peng et al., 1991; IC50 
is in the low micromolar range) is at least as high as against P2 receptors. Suramin is also an 
inhibitor of several enzymes, including 5′-nucleotidase (Hourani and Chown, 1989), 
something that is of particular concern when the compound is used to discriminate between 
P1 and P2 actions. 2–2′-Pyridylisatogen was reported to be a weakly selective antagonist of 
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the relaxant effects of ATP in smooth muscle (Spedding et al., 1975) but did not antagonize 
the effects of adenosine (Spedding and Weetman, 1976). Pyridoxalphosphate-6-
azophenyl-2′,4′-disulfonic acid, synthesized by Lambrecht and co-workers (1992), is a novel 
type of P2 antagonist with a potency at P2X receptors in the nanomolar range (Ziganshin et 
al., 1993). The displacement of [3H]αβMeATP was biphasic, suggesting multiple affinity 
sites or multiple receptor subtypes (Ziganshin et al., 1993). Reactive Blue 2 has been 
reported to selectively antagonize ATP actions at the P2Y subtype, although concentration 
and time of exposure are critical. The structures of a number of compounds useful for the 
study of P2 purinoceptors are shown in figure 4.
Molecular information concerning P2 purinoceptors is becoming available. Xenopus oocytes 
injected with mRNA from embryonic guinea pig brain (Fournier et al., 1990; Honoré et al., 
1991), promyelocytic leukemia cells (HL60; Murphy and Tiffany, 1990), J774 murine 
macrophage-like cells (Hickman et al., 1993; Nuttle et al., 1993), or guinea pig vas deferens 
(Russell et al., 1993) were conferred with the ability to respond to ATP. The pharmacology 
corresponded to that of several of the proposed P2 receptor subforms.
P2Y (Webb et al., 1993) and P2U purinoceptors (Lustig et al., 1993) have recently been 
cloned. As shown from figure 1, these receptors are more similar to each other than they are 
to adenosine receptors. Interestingly, they are not closer to the adenosine receptor than to 
other G-protein-coupled receptors. Based on such a comparison of these sequences with a 
more recently cloned ADP receptor, it has been proposed that the G-protein-coupled P2 
purinoceptors will constitute a distinct family within the superfamily of G-protein-coupled 
receptors (Barnard et al., 1994).
P2Y purinoceptor-mediated responses show different agonist pharmacology in a variety of 
tissues and preparations (Burnstock, 1991; Fischer et al., 1993), suggesting a 
subclassification of the “classic” P2Y purinoceptor. Other data suggest that the currently 
designated “P2U,” “P2T,” and “P2D” purinoceptor subtypes may have to be reclassified.
On these grounds it must be emphasized that the current classification of the P2 series must 
be considered unsatisfactory for the long term. When additional structural information is 
obtained and truly selective antagonists become available, a revised nomenclature will be 
established. Even now it is clear that there is a basis for distinguishing two major families of 
P2 purinoceptors, one coupled to intrinsic ion channels and the other coupled to G-proteins. 
For the transition period the IUPHAR Committee on Receptor Nomenclature and Drug 
Classification, in keeping with the proposal by Abbracchio and Burnstock (1994), 
recommends that any new subtypes of G-protein-coupled receptor be termed P2Y1, P2Y2, 
P2Y3,… purinoceptors and any new subtypes of intrinsic ion channel be termed P2X1, 
P2X2, P2X3,… purinoceptors. The 2X and 2Y are not subscripted, to avoid confusion with 
previous usage and to facilitate the use of lower case, as in p2y1, p2y2,… to refer to cloned 
receptors whose correspondence to a pharmacologically defined subtype has not been firmly 
established. Lower case is being used in this way in other IUPHAR nomenclatures, e.g., 
adrenoceptors, muscarinic cholinoceptors, and 5-hydroxytryptamine receptors. The term 
P2Z purinoceptor should be reserved for novel receptor structures that do not correspond to 
the P2X and P2Y purinoceptor structure. A possible example could be the mast cell P2 
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purinoceptor, if this is established to be a nonselective ion pore opened by ATP. Although 
not an ideal system of classification, it does allow consecutive numbering and obviates the 
need for arbitrary designation of letters when new subtypes are identified.
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Amino acid sequences of purinoceptors deduced from cloned DNAs, aligned for maximum 
homology. Note that the P2 receptor sequences belong to a completely different family than 
do the adenosine (P1) receptors. The adenosine receptors listed here are all from the rat: A1 
(Mahan et al., 1991), 326 amino acids; A2a (Fink et al., 1992; Furlong et al., 1992), 410 
amino acids; A2b, (Stehle et al., 1992), 332 amino acids; A3 (Meyerhof et al., 1991; Zhou et 
al., 1992), 319 amino acids. Other such recombinant sequences known are for the human 
(Salvatore et al., 1992; Libert et al., 1992; Townsend-Nicholson and Shine, 1992), canine 
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(Libert et al., 1991), and bovine (Olah et al., 1992; Tucker et al., 1992) A1 receptors; the 
human (Salvatore et al., 1992) and canine (Maenhaut et al., 1990) A2a receptors; and the 
human (Salvatore et al., 1992) A2b receptor, each of these is extremely homologous to the 
corresponding rat receptor. The rabbit A2 receptor was also found to be highly homologous, 
and genomic cloning revealed that the receptor gene has an intron (Bhattacharya et al., 
1993). The chicken P2yl receptor has 362 amino acids (Webb et al., 1993), and the mouse 
P2u receptor (Lustig et al., 1993) has 373 amino acids. The approximate start positions of 
the transmembrane helices, as designated on the basis of hydropathy plots, are shown by the 
symbols TM1 to TM7.
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Proposed models of A1 and A2A adenosine receptor proteins based on sequence analysis 
(van Galen et al., 1992) and computer-assisted molecular modeling (Ijzerman et al., 1992). 
The seven transmembrane helices (I through VII) are arranged in a counterclockwise 
orientation (looking from the extracellular side) according to the experimentally determined 
structure of bacteriorhodopsin. Actually, I and VII are in proximity, forming a barrel shape, 
which surrounds the ligand-binding site. Histidyl residues (H) in the sixth and seventh 
helices are proposed to hydrogen bond to adenosine, through the purine N6- and ribose 2′,3′ 
positions, respectively. The locations of cysteinyl residues (SH) and hypothetical disulfide 
bridges (S-S, Jacobson et al., 1993d) are indicated. Glycosylation occurs on the second 
extracellular loop (E-II) in both receptors. In the A1 receptor, a potential palmitoylation site 
(S-CO) is shown as forming an additional anchor of the carboxy-terminal segment in the 
phospholipid bilayer. Cytoplasmic segments show a hypothetical secondary structure (α and 
β), predicted using computational algorithms (van Galen et al., 1992)
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Ligands used to classify adenosine receptors. Adenosine agonists (a) include those that are 
selective for A1 receptors [N6-cyclopentyladenosine (CPA) > N6-cyclohexyladenosine 
(CHA) > N6(R-phenylisopropyl)-adenosine (R-PIA)], A2a receptors (2-[p-(2-car-
bonylethyl)-phenylethylamino]-5′N-ethylcarboxamidoadenosine (CG21680)>2-[(2-
aminoethylamino)carbonylethylphenylethylamino]-5′N-ethylcarboxamidoadenosine (APEC) 
> 2-phenylaminoadenosine (CV1808)), and A3 receptors [N6-benzyl-5′-N-ethyl-
carboxamidoadenosine (NECA)]. NECA and 2-chloroadenosine (2-C1ADO) are essentially 
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nonselective. Adenosine antagonists (b) include such that are A1 selective {l,3-dipropyl-8-
cyclopentylxanthine (CPX, or sometimes DPCPX); 8-cyclopentyltheophylline (CPT) [and 
xanthine amine congener (XAC)] |, thosethatareA2a,selective[8-(3-
chlorostryl)caffeine(CSC);1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine (KF 
17837)], moderately A2 selective [1,3-dimethyl-7-propylxanthine (DMPX) and 9-chloro-2-
(2-furanyl)-5,6-dihydro-[1,2,4]-triazolo[1,5]quinazolin-5-imine monome-
thanesulfonate(CGS 15943)}. Caffeine, theophylline, 3-isobutyl-1-methylxanthine (IBMX), 
and 8p-sulfophenyl theophylline are essentially nonselective. The latter compound 
penetrates the blood-brain barrier poorly. (For other abbreviations, see footnote to table 3).
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Ligands used to characterize P2 purinoceptors. The structures shown are of the D-isomers. 
Some studies have also been done on L-isomers. α,β-methylene (Me) ATP is a potent and 
selective P2X agonist. 8-(6-aminohexylamino)ATP is selective for P2Y vs. P2X receptors and 
may discriminate between subforms (Burnstock et al., 1994). UTP and 5-F-UTP are active at 
P2U but not at P2Y receptors. 2-MethylthioATP is active at P2Y but not at P2U receptors. 
None of these are very active at P2X receptors. The long-chain functionalized congeners 
(Fischer et al., 1993) 2-(p-nitrophenylthio)ATP and 2-(6-cyanhexylthio)ATP maintain or 
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increase potency at P2Yreceptors. The nitro derivative may discriminate between forms of 
P2X receptors. N6-methyl ATP may discriminate between forms of P2Y receptors. The 
structures of some compounds—suramin, pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic 
acid (PPADS), and Reactive Blue—that have antagonistic properties are also shown.
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TABLE 1
Original criteria for distinguishing two types of purinoceptors





  Methylxanthines* ADO > AMP > ADP > ATP† Yes‡ No§
P2 receptors
  Quinidine*
  Imidazolines No‡ Yes§
  2,2′-Pyridylisatogen ATP > ADP > AMP > ADO†
  Apamin
*
We still lack good antagonists at P2 receptors (see section III.B and Table 4). There are apparently adenosine receptors (A3 receptors, see below) 
where the classical methylxanthines are very poor antagonists.
†
Adenosine (ADO) and AMP do not activate P2 receptors. Adenine nucleotides may or may not be agonists at adenosine receptors.
‡
Not all adenosine receptors (P1 purinoceptors) affect cyclic AMP formation. Conversely, adenine nucleotides may affect cyclic AMP formation.
§
Not all effects of ATP or ADP are mediated through changes in prostaglandin formation. Adenosine effects on Ca2+ may be associated with 
prostaglandin formation.
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TABLE 2
Subdivision of purinoceptors into P1 and P2 types. Current recommendations
Receptor class P1 purinoceptors P2 purinoceptors









Whereas UTP is an endogenous compound and a ligand at some P2 purinoceptors, it remains to be shown that endogenous UTP acts via such 
receptors in vivo.
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